Orphazyme Pink Sheet Forecast - Naive Prediction
| OZYMF Stock | USD 90.00 0.00 0.00% |
Orphazyme Pink Sheet outlook is based on your current time horizon. We recommend always using this module together with an analysis of Orphazyme's historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 28th of January 2026 the relative strength index (rsi) of Orphazyme's share price is below 20 . This indicates that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using Orphazyme hype-based prediction, you can estimate the value of Orphazyme AS from the perspective of Orphazyme response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Orphazyme AS on the next trading day is expected to be 90.00 with a mean absolute deviation of 0.00 and the sum of the absolute errors of 0.00. Orphazyme after-hype prediction price | USD 90.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Orphazyme |
Orphazyme Additional Predictive Modules
Most predictive techniques to examine Orphazyme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Orphazyme using various technical indicators. When you analyze Orphazyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Orphazyme Naive Prediction Price Forecast For the 29th of January
Given 90 days horizon, the Naive Prediction forecasted value of Orphazyme AS on the next trading day is expected to be 90.00 with a mean absolute deviation of 0.00, mean absolute percentage error of 0.00, and the sum of the absolute errors of 0.00.Please note that although there have been many attempts to predict Orphazyme Pink Sheet prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Orphazyme's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Orphazyme Pink Sheet Forecast Pattern
| Backtest Orphazyme | Orphazyme Price Prediction | Buy or Sell Advice |
Orphazyme Forecasted Value
In the context of forecasting Orphazyme's Pink Sheet value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Orphazyme's downside and upside margins for the forecasting period are 90.00 and 90.00, respectively. We have considered Orphazyme's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Orphazyme pink sheet data series using in forecasting. Note that when a statistical model is used to represent Orphazyme pink sheet, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | -9.223372036854776E14 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0 |
| MAPE | Mean absolute percentage error | 0.0 |
| SAE | Sum of the absolute errors | 0.0 |
Predictive Modules for Orphazyme
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Orphazyme AS. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Orphazyme After-Hype Price Density Analysis
As far as predicting the price of Orphazyme at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Orphazyme or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Orphazyme, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Orphazyme Estimiated After-Hype Price Volatility
In the context of predicting Orphazyme's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Orphazyme's historical news coverage. Orphazyme's after-hype downside and upside margins for the prediction period are 90.00 and 90.00, respectively. We have considered Orphazyme's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Orphazyme is very steady at this time. Analysis and calculation of next after-hype price of Orphazyme AS is based on 3 months time horizon.
Orphazyme Pink Sheet Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Orphazyme is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Orphazyme backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Orphazyme, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 6 Events / Month | 1 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
90.00 | 90.00 | 0.00 |
|
Orphazyme Hype Timeline
Orphazyme AS is now traded for 90.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Orphazyme is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Orphazyme is about 0.0%, with the expected price after the next announcement by competition of 90.00. The company has price-to-book ratio of 0.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orphazyme AS recorded a loss per share of 2.54. The entity had not issued any dividends in recent years. Assuming the 90 days horizon the next expected press release will be in about 6 days. Check out Historical Fundamental Analysis of Orphazyme to cross-verify your projections.Orphazyme Related Hype Analysis
Having access to credible news sources related to Orphazyme's direct competition is more important than ever and may enhance your ability to predict Orphazyme's future price movements. Getting to know how Orphazyme's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Orphazyme may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| VAXX | Vaxxinity | 0.00 | 0 per month | 121.64 | 0.31 | 14,900 | (99.00) | 15,000 | |
| PXMD | PaxMedica Common Stock | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 4,998 | |
| SDCCQ | SmileDirectClub | 0.00 | 3 per month | 0.00 | 0.05 | 0.00 | 0.00 | 150.00 | |
| XSNX | NovAccess Global | 0.00 | 0 per month | 0.00 | 0.13 | 0.00 | 0.00 | 400.00 | |
| QBIO | Q BioMed | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NNLX | Nanologix | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TRVN | Trevena | 0.00 | 6 per month | 0.00 | 0.11 | 0.00 | 0.00 | 1,000.00 | |
| HLUN | HEALTHeUNIVERSE | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| USMJ | North American Cannabis | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EVLO | Evelo Biosciences | 0.01 | 8 per month | 0.00 | 0.07 | 0.00 | (20.00) | 460.00 |
Other Forecasting Options for Orphazyme
For every potential investor in Orphazyme, whether a beginner or expert, Orphazyme's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Orphazyme Pink Sheet price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Orphazyme. Basic forecasting techniques help filter out the noise by identifying Orphazyme's price trends.Orphazyme Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orphazyme pink sheet to make a market-neutral strategy. Peer analysis of Orphazyme could also be used in its relative valuation, which is a method of valuing Orphazyme by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Orphazyme Market Strength Events
Market strength indicators help investors to evaluate how Orphazyme pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Orphazyme shares will generate the highest return on investment. By undertsting and applying Orphazyme pink sheet market strength indicators, traders can identify Orphazyme AS entry and exit signals to maximize returns.
Story Coverage note for Orphazyme
The number of cover stories for Orphazyme depends on current market conditions and Orphazyme's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Orphazyme is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Orphazyme's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Other Information on Investing in Orphazyme Pink Sheet
Orphazyme financial ratios help investors to determine whether Orphazyme Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orphazyme with respect to the benefits of owning Orphazyme security.